Royalty Pharma officer proposes $236K share sale

The shares are identified as coming from an equity performance award granted August 7, 2026, and Merrill Lynch is listed as broker.

Rhea-AI Filing Summary

Royalty Pharma plc officer Marshall Urist reported a proposed sale of 4,126 shares, with an aggregate market value of $235,594.60, through Merrill Lynch; the approximate sale date is October 5, 2026. The shares are identified as Class A ordinary shares from an equity performance award granted August 7, 2026. Urist also reported sales of 9,099 shares on July 1, 2026, for $508,453.82, and 4,126 shares on September 28, 2026, for $238,812.88.

Key Figures

Shares proposed for sale: 4,126 shares Aggregate market value: $235,594.60 Shares outstanding: 445,277,344 shares +4 more

7 metrics

Shares proposed for sale 4,126 shares Proposed sale

Aggregate market value $235,594.60 Proposed sale

Shares outstanding 445,277,344 shares Listed in the securities information

Shares sold 9,099 shares July 1, 2026

Aggregate value of shares sold $508,453.82 July 1, 2026

Shares sold 4,126 shares September 28, 2026

Aggregate value of shares sold $238,812.88 September 28, 2026

Key Terms

Rule 144, Class A Ordinary Shares, Equity Performance Award

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Class A Ordinary Shares financial

"Class A Ordinary Shares"

Class A ordinary shares are a type of ownership stake in a company that typically grants voting rights to shareholders, allowing them to have a say in important company decisions. They often come with priority in receiving dividends or profits, making them attractive to investors seeking influence and potential income. These shares help distinguish different levels of ownership and rights within a company's stock structure.

Equity Performance Award financial

"Equity Performance Award"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many RPRX shares did Marshall Urist report for sale?

Marshall Urist, identified as an officer, reported 4,126 shares for sale, with an aggregate market value of $235,594.60. The approximate sale date is October 5, 2026, and Merrill Lynch is listed as broker.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/05/2026 - 04:03 PM Accepted by SEC EDGAR 10/05/2026 - 04:02 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001838139
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Royalty Pharma plc
SEC File Number	001-39329
Address of Issuer	110 EAST 59TH STREET NEW YORK NEW YORK 10022
Phone	(212) 883-0200
Name of Person for Whose Account the Securities are To Be Sold	Urist Marshall
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Merrill Lynch 225 Liberty Street Floor 37 New York NY 10281	4126	235594.60	445277344	10/05/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A Ordinary Shares	08/07/2026	Equity Performance Award	Royalty Pharma plc			4126	08/07/2026	Granted as part of issuer equity compensation program

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Marshall Urist 110 EAST 59TH STREET New York NY 10022	Common Stock	07/01/2026	9099	508453.82
Marshall Urist 110 EAST 59TH STREET New York NY 10022	Common Stock	09/28/2026	4126	238812.88

144: Remarks and Signature

Remarks
Date of Notice	10/05/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	06/26/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Marshall Urist
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)